ANIX
Anixa Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.07
+0.66%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +21.9%
- EBIT
- +18.8%
- EPS
- —
- Free cash flow
- +10.8%
- Operating cash flow
- +10.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -10.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.2%
- EBIT
- +15.4%
- Net income
- +13.0%
- EPS
- +12.8%
- Free cash flow
- +2.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026